Results 31 to 40 of about 590 (119)

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

, 2013
Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and maintenance of asthma. This study assessed the effects of tralokinumab, an investigational human IL-13-neutralising immunoglobulin G4 monoclonal antibody, in ...
Piper, Edward, Brightling, Christopher, Molfino, Nestor A., Oh, Chad, She, Dewei, Niven, Robert, Faggioni, Raffaella, Poon, Kwai, Kell, Chris, May, Richard D., Geba, Gregory P.   +10 more
core   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

Allergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally, Takeshi Yoshida, Shan Gao, Xueya Cai, Donald Y. M. Leung, Lisa A. Beck, Anna De Benedetto   +6 more
wiley   +1 more source

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) [PDF]

, 2020
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD).
Cork, M. J., Steffensen, L.A., Østerdal, M. L., Jensen, T N, Katoh, N, Lacour, J., Jensen, T.N., Wollenberg, A., Lynde, C., Østerdal, M.L., Cho, S H, Peris K., Simpson, E.L., Peris, K, Steffensen, L. A., Lacour, J.-P., Lacour, J-P, Spelman, L., Cork, M J, Simpson, E. L., Cork, M.J., Steffensen, L A, Guttman-Yassky, E, Katoh, N., Guttman-Yassky, E., Simpson, E L, Bang, B., Herranz, P., Peris, K., Cho, S. H., Blauvelt, A., Jensen, T. N., Østerdal, M L, Lesiak, A, Worm, M., Spelman, L, Saeki, H., Worm, M, Bang, B, Poulin, Y, Cho, S.H., Wollenberg, A, Herranz, P, Kircik, L., Guttman‐Yassky, E., Kircik, L, Kuznetsova, A, Blauvelt, A, Kuznetsova, A., ECZTRA 1 and ECZTRA 2 study investigators, Saeki, H, Lesiak, A., Poulin, Y., Lynde, C   +53 more
core   +1 more source

Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease, and patients with moderate-to-severe AD may require treatment with biologics in combination with topical corticosteroids (TCS).
Marni Wiseman, Marco Benvenuto, Liv Strømkjær, Asger Paludan-Müller, Lasse Ryttig, Anne Sohrt Petersen, Andreas Wollenberg   +6 more
doaj   +1 more source

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis

Pharmaceutics, 2023
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis:The Phase 3 ECZTRA 6 Randomized Clinical Trial [PDF]

, 2023
IMPORTANCE: Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited. OBJECTIVE: To evaluate the efficacy and safety of interleukin-13-targeted treatment with tralokinumab monotherapy in ...
Eric L. Simpson, Petra Arlert, Blauvelt, Andrew, Andreas Wollenberg, Wollenberg, Andreas, Shinichi Imafuku, Katja Wendicke Lophaven, H. Chih-ho Hong, Paller, Amy S, Andrew Blauvelt, Schuttelaar, Marie L A; id_orcid, Weily Soong, Marie L. A. Schuttelaar, Imafuku, Shinichi, Lise Soldbro, Lophaven, Katja Wendicke, Natacha Strange Vest, Soong, Weily, Simpson, Eric L, Flohr, Carsten, Azra Kurbasic, Carsten Flohr, Kurbasic, Azra, Vest, Natacha Strange, Anthony Bewley, Arlert, Petra, Amy S. Paller, Cork, Michael, Bewley, Anthony, Soldbro, Lise, Michael Cork, Hong, H Chih-Ho   +31 more
core   +1 more source

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA)

Dermatology and Therapy
Introduction The tralokinumab pre-filled pen was developed to improve patient convenience and deliver 300 mg tralokinumab (the recommended dose for most patients) with one injection.
Jennifer Soung, Vivian Laquer, Matthew Zirwas, Peter van Iperen, John C. Stinson, Katrine Lykke Albertsen, Linda Stein Gold   +6 more
doaj   +1 more source

Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents

Frontiers in Medicine, 2023
Atopic dermatitis (AD) is a chronic inflammatory disease with a heterogeneous pathogenesis correlated with dysregulation of the immune system and a prevalence of the T2-mediated immune pathway.
Carlo Caffarelli, Arianna Giannetti, Giuliana Giannì, Giampaolo Ricci   +3 more
doaj   +1 more source